XBiotech Inc.
Moat Score — XBiotech Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | XBiotech holds patents and proprietary know-how around its 'True Human' antibody-discovery platform, which has already produced one commercially validated asset (bermekimab, sold to Janssen for $750M). But with no approved products today and a rheumatology program undermined by compromised clinical-site data, the IP has real but unrealized value rather than a protected, revenue-generating franchise. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Owning in-house manufacturing and clinical trial operations on its Austin campus lets XBiotech avoid CRO/CMO markups on R&D spend, which is a genuine efficiency edge, but it is not a low-cost advantage in any commercial product sense since the company has no approved product being sold at all. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved products and no product revenue since its manufacturing/clinical-services agreements ended in 2023, XBiotech has no commercial pricing power to speak of today. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | As a clinical-stage biopharmaceutical company developing antibody therapeutics, XBiotech's business has no network effect dynamic — value does not increase with more users or participants on a platform. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | There are no commercial customers or prescribers locked into XBiotech products today, since nothing is approved or on the market; any future switching-cost dynamics would depend entirely on whether a pipeline candidate eventually reaches approval and physician/patient adoption. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | XBiotech is a small, 85-employee organization operating from a single Austin campus, funded by a large cash balance from its 2019 Janssen sale rather than product economics; this gives it runway but not a defensible scale position versus larger, better-funded biotech and pharma competitors chasing similar targets. |